Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

(2014) Benjamin M. Scirica et al.   CIRCULATION

The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications

(2014) Angelo Avogaro et al.   DIABETES CARE

The potential for renoprotection with incretin-based drugs

(2014) Tetsuhiro Tanaka et al.   KIDNEY INTERNATIONAL

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors

(2013) M. Barbieri et al.   ATHEROSCLEROSIS

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?

(2013) R. P. Shannon   DIABETES

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial

(2013) Julio Rosenstock et al.   Diabetes & Vascular Disease Research

C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study: Table 1

(2013) Odd Erik Johansen et al.   DIABETES CARE

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

(2013) D. M. Nathan et al.   DIABETES CARE

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

(2013) Yifei Zhang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

(2013) A. Goto et al.   BMJ-British Medical Journal

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury

(2011) Yumei Ye et al.   BASIC RESEARCH IN CARDIOLOGY

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

(2011) R. E. van Genugten et al.   DIABETES OBESITY & METABOLISM

Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1

(2011) Gian Paolo Fadini et al.   VASCULAR PHARMACOLOGY

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

(2009) Carolyn F Deacon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS